Treatment of Metachronous Metastatic Hormone-Sensitive Prostate Cancer With Enzalutamide and ADT
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Overall Survival of Men With Metachronous Metastatic Hormone-Sensitive Prostate Cancer Treated With Enzalutamide and Androgen Deprivation Therapy
Eur Urol 2021 May 21;[EPub Ahead of Print], CJ Sweeney, AJ Martin, MR Stockler, S Begbie, KN Chi, S Chowdhury, X Coskinas, M Frydenberg, WE Hague, LG Horvath, AM Joshua, NJ Lawrence, GM Marx, J McCaffrey, R McDermott, M McJannett, SA North, F Parnis, W Parulekar, DW Pook, MN Reaume, SK Sandhu, A Tan, TH Tan, A Thomson, E Tu, F Vera-Badillo, SG Williams, S Yip, AY Zhang, RR Zielinski, ID DavisFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.